Trade Names: | |
Synonyms: | |
Status: | Approved (1994) |
Entry Type: | Oligosaccharide |
Molecule Category: | Salt |
UNII: | 12M44VTJ7B |
Parent Compound: | DALTEPARIN |
Action | Mechanism of Action | Reference |
---|---|---|
ACTIVATOR | Antithrombin-III activator | FDA |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Venous Thromboembolism | 4 | D054556 | ClinicalTrials |
Severe Acute Respiratory Syndrome | 3 | D045169 | ClinicalTrials |
Renal Insufficiency, Chronic | 3 | D051436 | ClinicalTrials |
Thromboembolism | 3 | D013923 | ClinicalTrials |
Breast Neoplasms | 3 | D001943 | ClinicalTrials |
Prostatic Neoplasms, Castration-Resistant | 3 | D064129 | ClinicalTrials |
Lung Neoplasms | 3 | D008175 | ClinicalTrials |
Hepatic Veno-Occlusive Disease | 3 | D006504 | ClinicalTrials |
Brain Injuries | 3 | D001930 | ClinicalTrials |
Stroke | 3 | D020521 | ClinicalTrials |
Pregnancy | 3 | D011247 | ClinicalTrials |
Abortion, Habitual | 3 | D000026 | ClinicalTrials |
Colorectal Neoplasms | 3 | D015179 | ClinicalTrials |
Thrombophilia | 3 | D019851 | ClinicalTrials |
Pancreatic Neoplasms | 3 | D010190 | ClinicalTrials |
Diabetic Foot | 2 | D017719 | ClinicalTrials |
Ovarian Neoplasms | 2 | D010051 | ClinicalTrials |
Central Nervous System Neoplasms | 2 | D016543 | ClinicalTrials |
Anemia, Sickle Cell | 2 | D000755 | ClinicalTrials |
Shock, Septic | 2 | D012772 | ClinicalTrials |
Multiple Myeloma | 2 | D009101 | ClinicalTrials |
Carcinoma, Renal Cell | 1 | D002292 | ClinicalTrials |
Resources | Reference |
---|---|
ChEMBL | CHEMBL1201460 |
FDA SRS | 12M44VTJ7B |